All these evidences have led to the design of phase III Olympia trials which are currently investigating the activity of olaparib as single agent both in metastatic and adjuvant treatment of breast cancer patients with germ-line BRCA1-2 mutations. This evidence concerns the gene BRCA1 and breast cancer.